8-K: Oscar Health Announces Strong 2023 Results and Positive 2024 Outlook

Oscar Health reported strong 2023 financial results, exceeding expectations and setting a positive outlook for 2024, including projected total company adjusted EBITDA profitability.

Summary

• Oscar Health announced its financial results for the fourth quarter and full year ended December 31, 2023, showing significant improvements in key financial metrics.
• For the full year 2023, direct and assumed policy premiums totaled $6.6 billion, a 3% decrease year-over-year, while premiums earned increased by 47% to $5.7 billion.
• The Medical Loss Ratio (MLR) improved to 81.6%, a 370 basis point improvement year-over-year, and the InsuranceCo Combined Ratio improved to 99.5%, a 640 basis point improvement year-over-year.
• The company's net loss for 2023 was $271 million, an improvement of $339 million year-over-year, and the adjusted EBITDA loss was $45 million, an improvement of $417 million year-over-year.
• Oscar Health is projecting total revenue between $8.3 billion and $8.4 billion for 2024, with an MLR between 80.2% and 81.2%, an SG&A Expense Ratio between 20.5% and 21.0%, and a total company adjusted EBITDA between $125 million and $175 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant improvements in key financial metrics and the optimistic outlook for 2024, including projected profitability. While there are still losses, the trend is clearly positive.

Positives

• Oscar Health exceeded expectations for most core metrics in 2023.
• The company achieved Insurance Company Adjusted EBITDA profitability in 2023.
• There is a clear path to consolidated Adjusted EBITDA profitability in 2024.
• The company serves more than 1.3 million members.
• Oscar Health is focused on driving long-term sustainable margin expansion.
• The company saw improvements in both MLR and administrative cost efficiencies.
• The Adjusted Administrative Expense Ratio improved due to lower distribution expenses and higher net premiums.
• The company is introducing new metrics for 2024, including Total Revenue and SG&A Expense Ratio.

Negatives

• Direct and Assumed Policy Premiums decreased by 3% year-over-year to $6.6 billion for 2023.
• The company reported a net loss of $271 million for 2023, although this is an improvement year-over-year.
• The company reported an adjusted EBITDA loss of $45 million for 2023, although this is an improvement year-over-year.
• Membership decreased from 1,151,483 in 2022 to 1,036,283 in 2023.

Risks

• The company's ability to execute its strategy and manage growth effectively is a risk.
• The company faces heightened competition in the markets in which it participates.
• The company's ability to accurately estimate medical expenses or manage medical costs is a risk.
• Changes in federal or state laws or regulations, including the ACA, could impact the company.
• The company's ability to comply with ongoing regulatory requirements is a risk.
• The company's ability to maintain good relations with healthcare providers is a risk.
• Unanticipated results of risk adjustment programs could impact the company.
• The company's ability to utilize reinsurance to reduce capital requirements is a risk.
• The company faces the risk of unfavorable outcomes from lawsuits and claims.
• The company's ability to attract and retain qualified personnel is a risk.
• The company faces the risk of data security breaches.
• The company's ability to detect and prevent material weaknesses in internal controls is a risk.

Future Outlook

Oscar Health anticipates total revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, an SG&A Expense Ratio of 20.5% to 21.0%, and a total company adjusted EBITDA of $125 million to $175 million for 2024.

Management Comments

• Mark Bertolini, CEO of Oscar, stated that the company delivered on its commitment for Insurance Company Adjusted EBITDA profitability.
• Mark Bertolini, CEO of Oscar, stated that the company has a clear line of sight into consolidated Adjusted EBITDA profitability in 2024.
• Mark Bertolini, CEO of Oscar, stated that the company remains focused on driving long-term sustainable margin expansion.

Industry Context

This announcement reflects a trend in the health insurance industry towards improving profitability and managing medical costs effectively, with a focus on technology and efficiency. The company's focus on achieving adjusted EBITDA profitability aligns with investor expectations for sustainable growth in the healthcare sector.

Comparison to Industry Standards

• Oscar Health's improvement in Medical Loss Ratio to 81.6% is a positive sign, but it is still important to compare this to industry leaders like UnitedHealth Group, which typically operates with an MLR in the low 80s.
• The company's goal of achieving adjusted EBITDA profitability in 2024 is a key milestone, as many health insurance companies are focused on improving their bottom line.
• The projected SG&A Expense Ratio of 20.5% to 21.0% for 2024 is a critical metric to watch, as it indicates the company's ability to control administrative costs, which is comparable to other tech-enabled health insurers like Bright Health before its restructuring.
• Oscar's focus on technology and member engagement is a differentiator, but its ability to scale these initiatives and achieve consistent profitability will be key to its long-term success, similar to how companies like Alignment Healthcare are trying to leverage technology for better outcomes.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial results and the positive outlook for 2024.
• Employees may feel more secure with the company's improved financial position and path to profitability.
• Customers may benefit from the company's focus on improving healthcare services and controlling costs.
• Suppliers and creditors may view the company as a more stable and reliable partner.

Next Steps

• Oscar Health will host a conference call on February 7, 2024, to discuss the financial results.
• The company will file its Annual Report on Form 10-K for the year ended December 31, 2023, with the SEC.

Key Dates

Keywords

Oscar Health, financial results, healthcare technology, medical loss ratio, adjusted EBITDA, premiums, insurance, profitability, SG&A expense ratio, reinsurance